Ertugliflozin for type 2 diabetes (vol 42, pg 70, 2019)

被引：0
|
作者：
不详
机构：
来源：
AUSTRALIAN PRESCRIBER | 2019年 / 42卷 / 03期
关键词：
D O I：
10.18773/austprescr.2019.036
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：115 / 115
页数：1
相关论文
共 50 条
  • [41] ASSESSMENT OF LIVER FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS RECEIVING ERTUGLIFLOZIN
    Gallo, Silvina
    Calle, Roberto
    Terra, Steven
    Pong, Annpey
    Tarasenko, Lisa
    Raji, Annaswamy
    [J]. HEPATOLOGY, 2019, 70 : 1261A - 1261A
  • [42] Association of Hypoglycemia With Subsequent Dementia in Older Patients With Type 2 Diabetes Mellitus (vol 72, pg 1110, 2019)
    Mehta, Hemalkumar B.
    Mehta, Vinay
    Goodwin, James S.
    [J]. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2019, 74 (05): : 750 - 750
  • [43] THE NEW VIEWS ON THE STATE OF THE GUT MICROBIOTA IN OBESITY AND DIABETES MELLITUS TYPE 2 (vol 22, pg 253, 2019)
    Pokrovskaya, Elena V.
    Shamkhalova, Minara S.
    Shestakova, Marina V.
    [J]. DIABETES MELLITUS, 2019, 22 (04): : 403 - 404
  • [44] Hypothesis: Role of Reduced Hepatic Insulin Clearance in the Pathogenesis of Type 2 Diabetes (vol 68, pg 1709, 2019)
    Bergman, Richard N.
    Piccinini, Francesca
    Kabir, Morvarid
    Kolka, Cathryn M.
    Ader, Marilyn
    [J]. DIABETES, 2019, 68 (12) : 2350 - 2350
  • [45] C-peptide concentrations in patients with type 2 diabetes treated with insulin (vol 13, pg 3099, 2019)
    Uzunlulu, Mehmet
    Oguz, Aytekin
    Bahadir, Muzeyyen Arslan
    Erbakan, Ayse Naciye
    Keskinler, Mirac Vural
    Mesci, Banu Alpaslan
    [J]. DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2021, 15 (01) : 471 - 471
  • [46] Quality of life and metabolic control in type 2 diabetes mellitus diagnosed individuals (vol 13, pg 2827, 2019)
    Marte, Jenny L. Cepeda
    Ruiz-Matuk, Carlos
    Mota, Merary
    Perez, Sabrina
    Recio, Natasha
    Hernandez, Deysi
    Fernandez, Jose
    Porto, Jackie
    Ramos, Angel
    [J]. DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2021, 15 (01) : 472 - 472
  • [47] Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
    Cinti, Francesca
    Moffa, Simona
    Impronta, Flavia
    Cefalo, Chiara M. A.
    Sun, Vinsin A.
    Sorice, Gian Pio
    Mezza, Teresa
    Giaccari, Andrea
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 2905 - 2919
  • [48] Ertugliflozin in older patients with type 2 diabetes: an analysis from VERTIS CV
    Pratley, R. E.
    Cannon, C. P.
    Charbonnel, B.
    Cherney, D. Z. I.
    Cosentino, F.
    McGuire, D. K.
    Shih, W. J.
    Essex, M. N.
    Lawrence, D.
    Jones, P. L. S.
    Liu, J.
    Adamsons, I. A.
    Dagogo-Jack, S.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 30 - 31
  • [49] Assessment of adverse renal effects in patients with type 2 diabetes receiving ertugliflozin
    Terra, S. G.
    Patel, S.
    Hickman, A.
    Frederich, R.
    Lauring, B.
    Johnson, S.
    Huyck, S.
    Mancuso, J. P.
    [J]. DIABETOLOGIA, 2018, 61 : S300 - S301
  • [50] Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus
    Liu, Jie
    Tarasenko, Lisa
    Pong, Annpey
    Huyck, Susan
    Patel, Shrita
    Hickman, Anne
    Mancuso, James P.
    Ellison, Misoo C.
    Gantz, Ira
    Terra, Steven G.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (07) : 1097 - 1106
12345